White matter hyperintensities influence distal cortical β-amyloid accumulation in default mode network pathways
Doaa G Ali1,2, Ahmed A Bahrani1,3, Riham H El Khouli4
1Sanders-Brown Center on Aging, College of Medicine, University of Kentucky, Lexington, Kentucky, USA.
Brain and Behavior
|August 3, 2023
Summary
Small vessel disease (SVD) impacts amyloid-beta (Aβ) levels in the brain
Area of Science:
- Neurology
- Neuroimaging
- Alzheimer's Disease Research
Background:
- Cerebral small vessel disease (SVD) is implicated in Alzheimer's disease (AD) pathogenesis.
- The precise role of SVD in AD pathology remains unclear.
- Investigating the link between white matter hyperintensities (WMH) and amyloid-beta (Aβ) in cognitively unimpaired older adults is crucial.
Purpose of the Study:
- To test if white matter hyperintensities (WMH) influence amyloid-beta (Aβ) levels.
- To examine Aβ levels within default mode network (DMN) tracts and cortical regions.
- To explore SVD's contribution to preclinical AD pathology.
Main Methods:
- Analyzed Aβ-PET SUVr and WMH volumes in 72 cognitively unimpaired older adults (ADNI3).
- Utilized 3D MRI FLAIR for WMH volume assessment.
- Employed linear regression adjusted for age, sex, ApoE, and total brain volume.
Main Results:
- Increased WMH in the superior longitudinal fasciculus correlated with higher Aβ-PET SUVr in the inferior parietal lobule (p=0.011).
- This suggests a link between SVD in white matter pathways and Aβ deposition in the parietal cortex.
Conclusions:
- Findings indicate an association between parietal Aβ and SVD in downstream white matter pathways in preclinical AD.
- Further research is needed on the interplay between Aβ and white matter alterations in AD progression.
- Understanding these relationships is key to unraveling AD pathogenesis.
Related Concept Videos
Alzheimer's Disease: Overview
522
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
522
Amyloid Fibrils
5.5K
5.5K


